Global Radiopharmaceutical for Nuclear Medicine Supply, Demand and Key Producers, 2026-2032
The global Radiopharmaceutical for Nuclear Medicine market size is expected to reach $ 20045 million by 2032, rising at a market growth of 8.6% CAGR during the forecast period (2026-2032).
Radiopharmaceuticals for nuclear medicine are a class of specialized drugs that combine radioactive isotopes with biologically active molecules for in vivo diagnosis and therapy. Their primary functions include imaging organs or lesions using radioactive tracers and delivering targeted radiation to tumors or diseased tissues. These drugs encompass single-photon emission computed tomography (SPECT) tracers, positron emission tomography (PET) tracers, and therapeutic radiopharmaceuticals, widely applied in oncology, cardiovascular and cerebrovascular diseases, neurological disorders, and bone diseases. The key advantages of radiopharmaceuticals lie in their high sensitivity, quantifiability, non-invasiveness, and the ability to detect diseases at early stages while enabling individualized treatment planning. With advances in nuclear imaging and radiopharmaceutical production technologies, their role in precision medicine and personalized therapy is increasingly significant.The average gross profit margin of this product is 72%.
The rapidly growing demand for precision diagnostics and personalized therapy provides significant growth opportunities for the radiopharmaceutical market. The high prevalence of cancer and cardiovascular diseases continues to drive demand for both diagnostic and therapeutic applications. The adoption of advanced imaging technologies such as PET/CT and SPECT/CT has enhanced the clinical value of radiopharmaceuticals. Meanwhile, advancements in molecularly targeted and therapeutic radiopharmaceuticals are expanding clinical indications. Government support for early disease screening and precision medicine, combined with improvements in healthcare infrastructure, further fuels market growth. The production and use of radiopharmaceuticals involve highly radioactive materials, imposing strict safety, transportation, and regulatory compliance requirements. The short half-life of radioactive isotopes creates supply chain constraints, impacting product stability and availability. Long development cycles, high investment, and technical complexity limit rapid innovation. Additionally, stringent regulatory approval processes and reimbursement policies may restrict market access and pricing, while specialized clinical expertise requirements constrain adoption. Clinical demand is shifting toward high-sensitivity, low-dose, and personalized radiopharmaceuticals, requiring more precise imaging and therapeutic planning. The integration of diagnostic and therapeutic approaches is driving growth in therapeutic radiopharmaceutical demand. Expansion into primary care and specialized centers also increases demand for small-dose, rapidly prepared, and user-friendly products. The growing emphasis on individualized precision medicine has elevated the importance of multimodal imaging and targeted therapy, generating diversified market needs. Upstream materials for radiopharmaceuticals primarily include radioactive isotopes, chemical precursors, and labeling or synthesis reagents. Radioactive isotopes are the core material, with supply constrained by reactor or accelerator capacity and isotope half-life. Chemical precursors and labeling reagents directly determine drug purity, stability, and biocompatibility. High-purity and controlled processes are critical, as any material variability can impact clinical safety and efficacy. With advancements in domestic isotope production and synthesis technologies, upstream supply is gradually being localized, though stringent quality standards and process consistency remain essential.
This report studies the global Radiopharmaceutical for Nuclear Medicine demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Radiopharmaceutical for Nuclear Medicine, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Radiopharmaceutical for Nuclear Medicine that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Radiopharmaceutical for Nuclear Medicine total market, 2021-2032, (USD Million)
Global Radiopharmaceutical for Nuclear Medicine total market by region & country, CAGR, 2021-2032, (USD Million)
U.S. VS China: Radiopharmaceutical for Nuclear Medicine total market, key domestic companies, and share, (USD Million)
Global Radiopharmaceutical for Nuclear Medicine revenue by player, revenue and market share 2021-2026, (USD Million)
Global Radiopharmaceutical for Nuclear Medicine total market by Type, CAGR, 2021-2032, (USD Million)
Global Radiopharmaceutical for Nuclear Medicine total market by Application, CAGR, 2021-2032, (USD Million)
This report profiles major players in the global Radiopharmaceutical for Nuclear Medicine market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Cardinal Health, GE Healthcare, Lantheus Medical Imaging, Bayer, Eli Lilly, Bracco Imaging, Curium Pharma, Jubilant Pharmova, Aurobindo Pharma, Novartis, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Radiopharmaceutical for Nuclear Medicine market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Radiopharmaceutical for Nuclear Medicine Market, By Region:
1. How big is the global Radiopharmaceutical for Nuclear Medicine market?
2. What is the demand of the global Radiopharmaceutical for Nuclear Medicine market?
3. What is the year over year growth of the global Radiopharmaceutical for Nuclear Medicine market?
4. What is the total value of the global Radiopharmaceutical for Nuclear Medicine market?
5. Who are the Major Players in the global Radiopharmaceutical for Nuclear Medicine market?
6. What are the growth factors driving the market demand?
Radiopharmaceuticals for nuclear medicine are a class of specialized drugs that combine radioactive isotopes with biologically active molecules for in vivo diagnosis and therapy. Their primary functions include imaging organs or lesions using radioactive tracers and delivering targeted radiation to tumors or diseased tissues. These drugs encompass single-photon emission computed tomography (SPECT) tracers, positron emission tomography (PET) tracers, and therapeutic radiopharmaceuticals, widely applied in oncology, cardiovascular and cerebrovascular diseases, neurological disorders, and bone diseases. The key advantages of radiopharmaceuticals lie in their high sensitivity, quantifiability, non-invasiveness, and the ability to detect diseases at early stages while enabling individualized treatment planning. With advances in nuclear imaging and radiopharmaceutical production technologies, their role in precision medicine and personalized therapy is increasingly significant.The average gross profit margin of this product is 72%.
The rapidly growing demand for precision diagnostics and personalized therapy provides significant growth opportunities for the radiopharmaceutical market. The high prevalence of cancer and cardiovascular diseases continues to drive demand for both diagnostic and therapeutic applications. The adoption of advanced imaging technologies such as PET/CT and SPECT/CT has enhanced the clinical value of radiopharmaceuticals. Meanwhile, advancements in molecularly targeted and therapeutic radiopharmaceuticals are expanding clinical indications. Government support for early disease screening and precision medicine, combined with improvements in healthcare infrastructure, further fuels market growth. The production and use of radiopharmaceuticals involve highly radioactive materials, imposing strict safety, transportation, and regulatory compliance requirements. The short half-life of radioactive isotopes creates supply chain constraints, impacting product stability and availability. Long development cycles, high investment, and technical complexity limit rapid innovation. Additionally, stringent regulatory approval processes and reimbursement policies may restrict market access and pricing, while specialized clinical expertise requirements constrain adoption. Clinical demand is shifting toward high-sensitivity, low-dose, and personalized radiopharmaceuticals, requiring more precise imaging and therapeutic planning. The integration of diagnostic and therapeutic approaches is driving growth in therapeutic radiopharmaceutical demand. Expansion into primary care and specialized centers also increases demand for small-dose, rapidly prepared, and user-friendly products. The growing emphasis on individualized precision medicine has elevated the importance of multimodal imaging and targeted therapy, generating diversified market needs. Upstream materials for radiopharmaceuticals primarily include radioactive isotopes, chemical precursors, and labeling or synthesis reagents. Radioactive isotopes are the core material, with supply constrained by reactor or accelerator capacity and isotope half-life. Chemical precursors and labeling reagents directly determine drug purity, stability, and biocompatibility. High-purity and controlled processes are critical, as any material variability can impact clinical safety and efficacy. With advancements in domestic isotope production and synthesis technologies, upstream supply is gradually being localized, though stringent quality standards and process consistency remain essential.
This report studies the global Radiopharmaceutical for Nuclear Medicine demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Radiopharmaceutical for Nuclear Medicine, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Radiopharmaceutical for Nuclear Medicine that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Radiopharmaceutical for Nuclear Medicine total market, 2021-2032, (USD Million)
Global Radiopharmaceutical for Nuclear Medicine total market by region & country, CAGR, 2021-2032, (USD Million)
U.S. VS China: Radiopharmaceutical for Nuclear Medicine total market, key domestic companies, and share, (USD Million)
Global Radiopharmaceutical for Nuclear Medicine revenue by player, revenue and market share 2021-2026, (USD Million)
Global Radiopharmaceutical for Nuclear Medicine total market by Type, CAGR, 2021-2032, (USD Million)
Global Radiopharmaceutical for Nuclear Medicine total market by Application, CAGR, 2021-2032, (USD Million)
This report profiles major players in the global Radiopharmaceutical for Nuclear Medicine market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Cardinal Health, GE Healthcare, Lantheus Medical Imaging, Bayer, Eli Lilly, Bracco Imaging, Curium Pharma, Jubilant Pharmova, Aurobindo Pharma, Novartis, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Radiopharmaceutical for Nuclear Medicine market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Radiopharmaceutical for Nuclear Medicine Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- Diagnosis Nuclear Medicine
- Therapeutic Nuclear Medicine
- Technetium-99m
- Fluorine-18
- Iodine-123
- Iodine-131
- Lutetium-177
- Other
- Hospital
- Imaging Center
- Others
- Cardinal Health
- GE Healthcare
- Lantheus Medical Imaging
- Bayer
- Eli Lilly
- Bracco Imaging
- Curium Pharma
- Jubilant Pharmova
- Aurobindo Pharma
- Novartis
- Siemens
- NTP Radioisotopes
- ANSTO
- Polatom
- China Isotope & Radiation
- Yantai Dongcheng
- Seed Biological Pharmacy
1. How big is the global Radiopharmaceutical for Nuclear Medicine market?
2. What is the demand of the global Radiopharmaceutical for Nuclear Medicine market?
3. What is the year over year growth of the global Radiopharmaceutical for Nuclear Medicine market?
4. What is the total value of the global Radiopharmaceutical for Nuclear Medicine market?
5. Who are the Major Players in the global Radiopharmaceutical for Nuclear Medicine market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Radiopharmaceutical for Nuclear Medicine Introduction
1.2 World Radiopharmaceutical for Nuclear Medicine Market Size & Forecast (2021 & 2025 & 2032)
1.3 World Radiopharmaceutical for Nuclear Medicine Total Market by Region (by Headquarter Location)
1.3.1 World Radiopharmaceutical for Nuclear Medicine Market Size by Region (2021-2032), (by Headquarter Location)
1.3.2 United States Based Company Radiopharmaceutical for Nuclear Medicine Revenue (2021-2032)
1.3.3 China Based Company Radiopharmaceutical for Nuclear Medicine Revenue (2021-2032)
1.3.4 Europe Based Company Radiopharmaceutical for Nuclear Medicine Revenue (2021-2032)
1.3.5 Japan Based Company Radiopharmaceutical for Nuclear Medicine Revenue (2021-2032)
1.3.6 South Korea Based Company Radiopharmaceutical for Nuclear Medicine Revenue (2021-2032)
1.3.7 ASEAN Based Company Radiopharmaceutical for Nuclear Medicine Revenue (2021-2032)
1.3.8 India Based Company Radiopharmaceutical for Nuclear Medicine Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Radiopharmaceutical for Nuclear Medicine Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Major Market Trends
2 DEMAND SUMMARY
2.1 World Radiopharmaceutical for Nuclear Medicine Consumption Value (2021-2032)
2.2 World Radiopharmaceutical for Nuclear Medicine Consumption Value by Region
2.2.1 World Radiopharmaceutical for Nuclear Medicine Consumption Value by Region (2021-2026)
2.2.2 World Radiopharmaceutical for Nuclear Medicine Consumption Value Forecast by Region (2027-2032)
2.3 United States Radiopharmaceutical for Nuclear Medicine Consumption Value (2021-2032)
2.4 China Radiopharmaceutical for Nuclear Medicine Consumption Value (2021-2032)
2.5 Europe Radiopharmaceutical for Nuclear Medicine Consumption Value (2021-2032)
2.6 Japan Radiopharmaceutical for Nuclear Medicine Consumption Value (2021-2032)
2.7 South Korea Radiopharmaceutical for Nuclear Medicine Consumption Value (2021-2032)
2.8 ASEAN Radiopharmaceutical for Nuclear Medicine Consumption Value (2021-2032)
2.9 India Radiopharmaceutical for Nuclear Medicine Consumption Value (2021-2032)
3 WORLD RADIOPHARMACEUTICAL FOR NUCLEAR MEDICINE COMPANIES COMPETITIVE ANALYSIS
3.1 World Radiopharmaceutical for Nuclear Medicine Revenue by Player (2021-2026)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Radiopharmaceutical for Nuclear Medicine Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Radiopharmaceutical for Nuclear Medicine in 2025
3.2.3 Global Concentration Ratios (CR8) for Radiopharmaceutical for Nuclear Medicine in 2025
3.3 Radiopharmaceutical for Nuclear Medicine Company Evaluation Quadrant
3.4 Radiopharmaceutical for Nuclear Medicine Market: Overall Company Footprint Analysis
3.4.1 Radiopharmaceutical for Nuclear Medicine Market: Region Footprint
3.4.2 Radiopharmaceutical for Nuclear Medicine Market: Company Product Type Footprint
3.4.3 Radiopharmaceutical for Nuclear Medicine Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Radiopharmaceutical for Nuclear Medicine Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Radiopharmaceutical for Nuclear Medicine Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
4.1.2 United States VS China: Radiopharmaceutical for Nuclear Medicine Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: Radiopharmaceutical for Nuclear Medicine Consumption Value Comparison
4.2.1 United States VS China: Radiopharmaceutical for Nuclear Medicine Consumption Value Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Radiopharmaceutical for Nuclear Medicine Consumption Value Market Share Comparison (2021 & 2025 & 2032)
4.3 United States Based Radiopharmaceutical for Nuclear Medicine Companies and Market Share, 2021-2026
4.3.1 United States Based Radiopharmaceutical for Nuclear Medicine Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Radiopharmaceutical for Nuclear Medicine Revenue, (2021-2026)
4.4 China Based Companies Radiopharmaceutical for Nuclear Medicine Revenue and Market Share, 2021-2026
4.4.1 China Based Radiopharmaceutical for Nuclear Medicine Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Radiopharmaceutical for Nuclear Medicine Revenue, (2021-2026)
4.5 Rest of World Based Radiopharmaceutical for Nuclear Medicine Companies and Market Share, 2021-2026
4.5.1 Rest of World Based Radiopharmaceutical for Nuclear Medicine Companies, Headquarters (Province, Country)
4.5.2 Rest of World Based Companies Radiopharmaceutical for Nuclear Medicine Revenue (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Radiopharmaceutical for Nuclear Medicine Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 Diagnosis Nuclear Medicine
5.2.2 Therapeutic Nuclear Medicine
5.3 Market Segment by Type
5.3.1 World Radiopharmaceutical for Nuclear Medicine Market Size by Type (2021-2026)
5.3.2 World Radiopharmaceutical for Nuclear Medicine Market Size by Type (2027-2032)
5.3.3 World Radiopharmaceutical for Nuclear Medicine Market Size Market Share by Type (2027-2032)
6 MARKET ANALYSIS BY DISEASE
6.1 World Radiopharmaceutical for Nuclear Medicine Market Size Overview by Disease: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Disease
6.2.1 Technetium-99m
6.2.2 Fluorine-18
6.2.3 Iodine-123
6.2.4 Iodine-131
6.2.5 Lutetium-177
6.2.6 Other
6.3 Market Segment by Disease
6.3.1 World Radiopharmaceutical for Nuclear Medicine Market Size by Disease (2021-2026)
6.3.2 World Radiopharmaceutical for Nuclear Medicine Market Size by Disease (2027-2032)
6.3.3 World Radiopharmaceutical for Nuclear Medicine Market Size Market Share by Disease (2027-2032)
7 MARKET ANALYSIS BY APPLICATION
7.1 World Radiopharmaceutical for Nuclear Medicine Market Size Overview by Application: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Application
7.2.1 Hospital
7.2.2 Imaging Center
7.2.3 Others
7.3 Market Segment by Application
7.3.1 World Radiopharmaceutical for Nuclear Medicine Market Size by Application (2021-2026)
7.3.2 World Radiopharmaceutical for Nuclear Medicine Market Size by Application (2027-2032)
7.3.3 World Radiopharmaceutical for Nuclear Medicine Market Size Market Share by Application (2021-2032)
8 COMPANY PROFILES
8.1 Cardinal Health
8.1.1 Cardinal Health Details
8.1.2 Cardinal Health Major Business
8.1.3 Cardinal Health Radiopharmaceutical for Nuclear Medicine Product and Services
8.1.4 Cardinal Health Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026)
8.1.5 Cardinal Health Recent Developments/Updates
8.1.6 Cardinal Health Competitive Strengths & Weaknesses
8.2 GE Healthcare
8.2.1 GE Healthcare Details
8.2.2 GE Healthcare Major Business
8.2.3 GE Healthcare Radiopharmaceutical for Nuclear Medicine Product and Services
8.2.4 GE Healthcare Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026)
8.2.5 GE Healthcare Recent Developments/Updates
8.2.6 GE Healthcare Competitive Strengths & Weaknesses
8.3 Lantheus Medical Imaging
8.3.1 Lantheus Medical Imaging Details
8.3.2 Lantheus Medical Imaging Major Business
8.3.3 Lantheus Medical Imaging Radiopharmaceutical for Nuclear Medicine Product and Services
8.3.4 Lantheus Medical Imaging Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026)
8.3.5 Lantheus Medical Imaging Recent Developments/Updates
8.3.6 Lantheus Medical Imaging Competitive Strengths & Weaknesses
8.4 Bayer
8.4.1 Bayer Details
8.4.2 Bayer Major Business
8.4.3 Bayer Radiopharmaceutical for Nuclear Medicine Product and Services
8.4.4 Bayer Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026)
8.4.5 Bayer Recent Developments/Updates
8.4.6 Bayer Competitive Strengths & Weaknesses
8.5 Eli Lilly
8.5.1 Eli Lilly Details
8.5.2 Eli Lilly Major Business
8.5.3 Eli Lilly Radiopharmaceutical for Nuclear Medicine Product and Services
8.5.4 Eli Lilly Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026)
8.5.5 Eli Lilly Recent Developments/Updates
8.5.6 Eli Lilly Competitive Strengths & Weaknesses
8.6 Bracco Imaging
8.6.1 Bracco Imaging Details
8.6.2 Bracco Imaging Major Business
8.6.3 Bracco Imaging Radiopharmaceutical for Nuclear Medicine Product and Services
8.6.4 Bracco Imaging Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026)
8.6.5 Bracco Imaging Recent Developments/Updates
8.6.6 Bracco Imaging Competitive Strengths & Weaknesses
8.7 Curium Pharma
8.7.1 Curium Pharma Details
8.7.2 Curium Pharma Major Business
8.7.3 Curium Pharma Radiopharmaceutical for Nuclear Medicine Product and Services
8.7.4 Curium Pharma Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026)
8.7.5 Curium Pharma Recent Developments/Updates
8.7.6 Curium Pharma Competitive Strengths & Weaknesses
8.8 Jubilant Pharmova
8.8.1 Jubilant Pharmova Details
8.8.2 Jubilant Pharmova Major Business
8.8.3 Jubilant Pharmova Radiopharmaceutical for Nuclear Medicine Product and Services
8.8.4 Jubilant Pharmova Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026)
8.8.5 Jubilant Pharmova Recent Developments/Updates
8.8.6 Jubilant Pharmova Competitive Strengths & Weaknesses
8.9 Aurobindo Pharma
8.9.1 Aurobindo Pharma Details
8.9.2 Aurobindo Pharma Major Business
8.9.3 Aurobindo Pharma Radiopharmaceutical for Nuclear Medicine Product and Services
8.9.4 Aurobindo Pharma Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026)
8.9.5 Aurobindo Pharma Recent Developments/Updates
8.9.6 Aurobindo Pharma Competitive Strengths & Weaknesses
8.10 Novartis
8.10.1 Novartis Details
8.10.2 Novartis Major Business
8.10.3 Novartis Radiopharmaceutical for Nuclear Medicine Product and Services
8.10.4 Novartis Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026)
8.10.5 Novartis Recent Developments/Updates
8.10.6 Novartis Competitive Strengths & Weaknesses
8.11 Siemens
8.11.1 Siemens Details
8.11.2 Siemens Major Business
8.11.3 Siemens Radiopharmaceutical for Nuclear Medicine Product and Services
8.11.4 Siemens Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026)
8.11.5 Siemens Recent Developments/Updates
8.11.6 Siemens Competitive Strengths & Weaknesses
8.12 NTP Radioisotopes
8.12.1 NTP Radioisotopes Details
8.12.2 NTP Radioisotopes Major Business
8.12.3 NTP Radioisotopes Radiopharmaceutical for Nuclear Medicine Product and Services
8.12.4 NTP Radioisotopes Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026)
8.12.5 NTP Radioisotopes Recent Developments/Updates
8.12.6 NTP Radioisotopes Competitive Strengths & Weaknesses
8.13 ANSTO
8.13.1 ANSTO Details
8.13.2 ANSTO Major Business
8.13.3 ANSTO Radiopharmaceutical for Nuclear Medicine Product and Services
8.13.4 ANSTO Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026)
8.13.5 ANSTO Recent Developments/Updates
8.13.6 ANSTO Competitive Strengths & Weaknesses
8.14 Polatom
8.14.1 Polatom Details
8.14.2 Polatom Major Business
8.14.3 Polatom Radiopharmaceutical for Nuclear Medicine Product and Services
8.14.4 Polatom Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026)
8.14.5 Polatom Recent Developments/Updates
8.14.6 Polatom Competitive Strengths & Weaknesses
8.15 China Isotope & Radiation
8.15.1 China Isotope & Radiation Details
8.15.2 China Isotope & Radiation Major Business
8.15.3 China Isotope & Radiation Radiopharmaceutical for Nuclear Medicine Product and Services
8.15.4 China Isotope & Radiation Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026)
8.15.5 China Isotope & Radiation Recent Developments/Updates
8.15.6 China Isotope & Radiation Competitive Strengths & Weaknesses
8.16 Yantai Dongcheng
8.16.1 Yantai Dongcheng Details
8.16.2 Yantai Dongcheng Major Business
8.16.3 Yantai Dongcheng Radiopharmaceutical for Nuclear Medicine Product and Services
8.16.4 Yantai Dongcheng Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026)
8.16.5 Yantai Dongcheng Recent Developments/Updates
8.16.6 Yantai Dongcheng Competitive Strengths & Weaknesses
8.17 Seed Biological Pharmacy
8.17.1 Seed Biological Pharmacy Details
8.17.2 Seed Biological Pharmacy Major Business
8.17.3 Seed Biological Pharmacy Radiopharmaceutical for Nuclear Medicine Product and Services
8.17.4 Seed Biological Pharmacy Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026)
8.17.5 Seed Biological Pharmacy Recent Developments/Updates
8.17.6 Seed Biological Pharmacy Competitive Strengths & Weaknesses
9 INDUSTRY CHAIN ANALYSIS
9.1 Radiopharmaceutical for Nuclear Medicine Industry Chain
9.2 Radiopharmaceutical for Nuclear Medicine Upstream Analysis
9.3 Radiopharmaceutical for Nuclear Medicine Midstream Analysis
9.4 Radiopharmaceutical for Nuclear Medicine Downstream Analysis
10 RESEARCH FINDINGS AND CONCLUSION
11 APPENDIX
11.1 Methodology
11.2 Research Process and Data Source
11.3 Disclaimer
1.1 Radiopharmaceutical for Nuclear Medicine Introduction
1.2 World Radiopharmaceutical for Nuclear Medicine Market Size & Forecast (2021 & 2025 & 2032)
1.3 World Radiopharmaceutical for Nuclear Medicine Total Market by Region (by Headquarter Location)
1.3.1 World Radiopharmaceutical for Nuclear Medicine Market Size by Region (2021-2032), (by Headquarter Location)
1.3.2 United States Based Company Radiopharmaceutical for Nuclear Medicine Revenue (2021-2032)
1.3.3 China Based Company Radiopharmaceutical for Nuclear Medicine Revenue (2021-2032)
1.3.4 Europe Based Company Radiopharmaceutical for Nuclear Medicine Revenue (2021-2032)
1.3.5 Japan Based Company Radiopharmaceutical for Nuclear Medicine Revenue (2021-2032)
1.3.6 South Korea Based Company Radiopharmaceutical for Nuclear Medicine Revenue (2021-2032)
1.3.7 ASEAN Based Company Radiopharmaceutical for Nuclear Medicine Revenue (2021-2032)
1.3.8 India Based Company Radiopharmaceutical for Nuclear Medicine Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Radiopharmaceutical for Nuclear Medicine Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Major Market Trends
2 DEMAND SUMMARY
2.1 World Radiopharmaceutical for Nuclear Medicine Consumption Value (2021-2032)
2.2 World Radiopharmaceutical for Nuclear Medicine Consumption Value by Region
2.2.1 World Radiopharmaceutical for Nuclear Medicine Consumption Value by Region (2021-2026)
2.2.2 World Radiopharmaceutical for Nuclear Medicine Consumption Value Forecast by Region (2027-2032)
2.3 United States Radiopharmaceutical for Nuclear Medicine Consumption Value (2021-2032)
2.4 China Radiopharmaceutical for Nuclear Medicine Consumption Value (2021-2032)
2.5 Europe Radiopharmaceutical for Nuclear Medicine Consumption Value (2021-2032)
2.6 Japan Radiopharmaceutical for Nuclear Medicine Consumption Value (2021-2032)
2.7 South Korea Radiopharmaceutical for Nuclear Medicine Consumption Value (2021-2032)
2.8 ASEAN Radiopharmaceutical for Nuclear Medicine Consumption Value (2021-2032)
2.9 India Radiopharmaceutical for Nuclear Medicine Consumption Value (2021-2032)
3 WORLD RADIOPHARMACEUTICAL FOR NUCLEAR MEDICINE COMPANIES COMPETITIVE ANALYSIS
3.1 World Radiopharmaceutical for Nuclear Medicine Revenue by Player (2021-2026)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Radiopharmaceutical for Nuclear Medicine Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Radiopharmaceutical for Nuclear Medicine in 2025
3.2.3 Global Concentration Ratios (CR8) for Radiopharmaceutical for Nuclear Medicine in 2025
3.3 Radiopharmaceutical for Nuclear Medicine Company Evaluation Quadrant
3.4 Radiopharmaceutical for Nuclear Medicine Market: Overall Company Footprint Analysis
3.4.1 Radiopharmaceutical for Nuclear Medicine Market: Region Footprint
3.4.2 Radiopharmaceutical for Nuclear Medicine Market: Company Product Type Footprint
3.4.3 Radiopharmaceutical for Nuclear Medicine Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Radiopharmaceutical for Nuclear Medicine Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Radiopharmaceutical for Nuclear Medicine Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
4.1.2 United States VS China: Radiopharmaceutical for Nuclear Medicine Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: Radiopharmaceutical for Nuclear Medicine Consumption Value Comparison
4.2.1 United States VS China: Radiopharmaceutical for Nuclear Medicine Consumption Value Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Radiopharmaceutical for Nuclear Medicine Consumption Value Market Share Comparison (2021 & 2025 & 2032)
4.3 United States Based Radiopharmaceutical for Nuclear Medicine Companies and Market Share, 2021-2026
4.3.1 United States Based Radiopharmaceutical for Nuclear Medicine Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Radiopharmaceutical for Nuclear Medicine Revenue, (2021-2026)
4.4 China Based Companies Radiopharmaceutical for Nuclear Medicine Revenue and Market Share, 2021-2026
4.4.1 China Based Radiopharmaceutical for Nuclear Medicine Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Radiopharmaceutical for Nuclear Medicine Revenue, (2021-2026)
4.5 Rest of World Based Radiopharmaceutical for Nuclear Medicine Companies and Market Share, 2021-2026
4.5.1 Rest of World Based Radiopharmaceutical for Nuclear Medicine Companies, Headquarters (Province, Country)
4.5.2 Rest of World Based Companies Radiopharmaceutical for Nuclear Medicine Revenue (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Radiopharmaceutical for Nuclear Medicine Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 Diagnosis Nuclear Medicine
5.2.2 Therapeutic Nuclear Medicine
5.3 Market Segment by Type
5.3.1 World Radiopharmaceutical for Nuclear Medicine Market Size by Type (2021-2026)
5.3.2 World Radiopharmaceutical for Nuclear Medicine Market Size by Type (2027-2032)
5.3.3 World Radiopharmaceutical for Nuclear Medicine Market Size Market Share by Type (2027-2032)
6 MARKET ANALYSIS BY DISEASE
6.1 World Radiopharmaceutical for Nuclear Medicine Market Size Overview by Disease: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Disease
6.2.1 Technetium-99m
6.2.2 Fluorine-18
6.2.3 Iodine-123
6.2.4 Iodine-131
6.2.5 Lutetium-177
6.2.6 Other
6.3 Market Segment by Disease
6.3.1 World Radiopharmaceutical for Nuclear Medicine Market Size by Disease (2021-2026)
6.3.2 World Radiopharmaceutical for Nuclear Medicine Market Size by Disease (2027-2032)
6.3.3 World Radiopharmaceutical for Nuclear Medicine Market Size Market Share by Disease (2027-2032)
7 MARKET ANALYSIS BY APPLICATION
7.1 World Radiopharmaceutical for Nuclear Medicine Market Size Overview by Application: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Application
7.2.1 Hospital
7.2.2 Imaging Center
7.2.3 Others
7.3 Market Segment by Application
7.3.1 World Radiopharmaceutical for Nuclear Medicine Market Size by Application (2021-2026)
7.3.2 World Radiopharmaceutical for Nuclear Medicine Market Size by Application (2027-2032)
7.3.3 World Radiopharmaceutical for Nuclear Medicine Market Size Market Share by Application (2021-2032)
8 COMPANY PROFILES
8.1 Cardinal Health
8.1.1 Cardinal Health Details
8.1.2 Cardinal Health Major Business
8.1.3 Cardinal Health Radiopharmaceutical for Nuclear Medicine Product and Services
8.1.4 Cardinal Health Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026)
8.1.5 Cardinal Health Recent Developments/Updates
8.1.6 Cardinal Health Competitive Strengths & Weaknesses
8.2 GE Healthcare
8.2.1 GE Healthcare Details
8.2.2 GE Healthcare Major Business
8.2.3 GE Healthcare Radiopharmaceutical for Nuclear Medicine Product and Services
8.2.4 GE Healthcare Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026)
8.2.5 GE Healthcare Recent Developments/Updates
8.2.6 GE Healthcare Competitive Strengths & Weaknesses
8.3 Lantheus Medical Imaging
8.3.1 Lantheus Medical Imaging Details
8.3.2 Lantheus Medical Imaging Major Business
8.3.3 Lantheus Medical Imaging Radiopharmaceutical for Nuclear Medicine Product and Services
8.3.4 Lantheus Medical Imaging Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026)
8.3.5 Lantheus Medical Imaging Recent Developments/Updates
8.3.6 Lantheus Medical Imaging Competitive Strengths & Weaknesses
8.4 Bayer
8.4.1 Bayer Details
8.4.2 Bayer Major Business
8.4.3 Bayer Radiopharmaceutical for Nuclear Medicine Product and Services
8.4.4 Bayer Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026)
8.4.5 Bayer Recent Developments/Updates
8.4.6 Bayer Competitive Strengths & Weaknesses
8.5 Eli Lilly
8.5.1 Eli Lilly Details
8.5.2 Eli Lilly Major Business
8.5.3 Eli Lilly Radiopharmaceutical for Nuclear Medicine Product and Services
8.5.4 Eli Lilly Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026)
8.5.5 Eli Lilly Recent Developments/Updates
8.5.6 Eli Lilly Competitive Strengths & Weaknesses
8.6 Bracco Imaging
8.6.1 Bracco Imaging Details
8.6.2 Bracco Imaging Major Business
8.6.3 Bracco Imaging Radiopharmaceutical for Nuclear Medicine Product and Services
8.6.4 Bracco Imaging Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026)
8.6.5 Bracco Imaging Recent Developments/Updates
8.6.6 Bracco Imaging Competitive Strengths & Weaknesses
8.7 Curium Pharma
8.7.1 Curium Pharma Details
8.7.2 Curium Pharma Major Business
8.7.3 Curium Pharma Radiopharmaceutical for Nuclear Medicine Product and Services
8.7.4 Curium Pharma Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026)
8.7.5 Curium Pharma Recent Developments/Updates
8.7.6 Curium Pharma Competitive Strengths & Weaknesses
8.8 Jubilant Pharmova
8.8.1 Jubilant Pharmova Details
8.8.2 Jubilant Pharmova Major Business
8.8.3 Jubilant Pharmova Radiopharmaceutical for Nuclear Medicine Product and Services
8.8.4 Jubilant Pharmova Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026)
8.8.5 Jubilant Pharmova Recent Developments/Updates
8.8.6 Jubilant Pharmova Competitive Strengths & Weaknesses
8.9 Aurobindo Pharma
8.9.1 Aurobindo Pharma Details
8.9.2 Aurobindo Pharma Major Business
8.9.3 Aurobindo Pharma Radiopharmaceutical for Nuclear Medicine Product and Services
8.9.4 Aurobindo Pharma Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026)
8.9.5 Aurobindo Pharma Recent Developments/Updates
8.9.6 Aurobindo Pharma Competitive Strengths & Weaknesses
8.10 Novartis
8.10.1 Novartis Details
8.10.2 Novartis Major Business
8.10.3 Novartis Radiopharmaceutical for Nuclear Medicine Product and Services
8.10.4 Novartis Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026)
8.10.5 Novartis Recent Developments/Updates
8.10.6 Novartis Competitive Strengths & Weaknesses
8.11 Siemens
8.11.1 Siemens Details
8.11.2 Siemens Major Business
8.11.3 Siemens Radiopharmaceutical for Nuclear Medicine Product and Services
8.11.4 Siemens Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026)
8.11.5 Siemens Recent Developments/Updates
8.11.6 Siemens Competitive Strengths & Weaknesses
8.12 NTP Radioisotopes
8.12.1 NTP Radioisotopes Details
8.12.2 NTP Radioisotopes Major Business
8.12.3 NTP Radioisotopes Radiopharmaceutical for Nuclear Medicine Product and Services
8.12.4 NTP Radioisotopes Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026)
8.12.5 NTP Radioisotopes Recent Developments/Updates
8.12.6 NTP Radioisotopes Competitive Strengths & Weaknesses
8.13 ANSTO
8.13.1 ANSTO Details
8.13.2 ANSTO Major Business
8.13.3 ANSTO Radiopharmaceutical for Nuclear Medicine Product and Services
8.13.4 ANSTO Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026)
8.13.5 ANSTO Recent Developments/Updates
8.13.6 ANSTO Competitive Strengths & Weaknesses
8.14 Polatom
8.14.1 Polatom Details
8.14.2 Polatom Major Business
8.14.3 Polatom Radiopharmaceutical for Nuclear Medicine Product and Services
8.14.4 Polatom Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026)
8.14.5 Polatom Recent Developments/Updates
8.14.6 Polatom Competitive Strengths & Weaknesses
8.15 China Isotope & Radiation
8.15.1 China Isotope & Radiation Details
8.15.2 China Isotope & Radiation Major Business
8.15.3 China Isotope & Radiation Radiopharmaceutical for Nuclear Medicine Product and Services
8.15.4 China Isotope & Radiation Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026)
8.15.5 China Isotope & Radiation Recent Developments/Updates
8.15.6 China Isotope & Radiation Competitive Strengths & Weaknesses
8.16 Yantai Dongcheng
8.16.1 Yantai Dongcheng Details
8.16.2 Yantai Dongcheng Major Business
8.16.3 Yantai Dongcheng Radiopharmaceutical for Nuclear Medicine Product and Services
8.16.4 Yantai Dongcheng Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026)
8.16.5 Yantai Dongcheng Recent Developments/Updates
8.16.6 Yantai Dongcheng Competitive Strengths & Weaknesses
8.17 Seed Biological Pharmacy
8.17.1 Seed Biological Pharmacy Details
8.17.2 Seed Biological Pharmacy Major Business
8.17.3 Seed Biological Pharmacy Radiopharmaceutical for Nuclear Medicine Product and Services
8.17.4 Seed Biological Pharmacy Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026)
8.17.5 Seed Biological Pharmacy Recent Developments/Updates
8.17.6 Seed Biological Pharmacy Competitive Strengths & Weaknesses
9 INDUSTRY CHAIN ANALYSIS
9.1 Radiopharmaceutical for Nuclear Medicine Industry Chain
9.2 Radiopharmaceutical for Nuclear Medicine Upstream Analysis
9.3 Radiopharmaceutical for Nuclear Medicine Midstream Analysis
9.4 Radiopharmaceutical for Nuclear Medicine Downstream Analysis
10 RESEARCH FINDINGS AND CONCLUSION
11 APPENDIX
11.1 Methodology
11.2 Research Process and Data Source
11.3 Disclaimer
LIST OF TABLES
Table 1. World Radiopharmaceutical for Nuclear Medicine Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World Radiopharmaceutical for Nuclear Medicine Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World Radiopharmaceutical for Nuclear Medicine Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World Radiopharmaceutical for Nuclear Medicine Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World Radiopharmaceutical for Nuclear Medicine Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Radiopharmaceutical for Nuclear Medicine Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World Radiopharmaceutical for Nuclear Medicine Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World Radiopharmaceutical for Nuclear Medicine Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World Radiopharmaceutical for Nuclear Medicine Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key Radiopharmaceutical for Nuclear Medicine Players in 2025
Table 12. World Radiopharmaceutical for Nuclear Medicine Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global Radiopharmaceutical for Nuclear Medicine Company Evaluation Quadrant
Table 14. Head Office of Key Radiopharmaceutical for Nuclear Medicine Players
Table 15. Radiopharmaceutical for Nuclear Medicine Market: Company Product Type Footprint
Table 16. Radiopharmaceutical for Nuclear Medicine Market: Company Product Application Footprint
Table 17. Radiopharmaceutical for Nuclear Medicine Mergers & Acquisitions Activity
Table 18. United States VS China Radiopharmaceutical for Nuclear Medicine Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China Radiopharmaceutical for Nuclear Medicine Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 20. United States Based Radiopharmaceutical for Nuclear Medicine Companies, Headquarters (States, Country)
Table 21. United States Based Companies Radiopharmaceutical for Nuclear Medicine Revenue, (2021-2026) & (USD Million)
Table 22. United States Based Companies Radiopharmaceutical for Nuclear Medicine Revenue Market Share (2021-2026)
Table 23. China Based Radiopharmaceutical for Nuclear Medicine Companies, Headquarters (Province, Country)
Table 24. China Based Companies Radiopharmaceutical for Nuclear Medicine Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies Radiopharmaceutical for Nuclear Medicine Revenue Market Share (2021-2026)
Table 26. Rest of World Based Radiopharmaceutical for Nuclear Medicine Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies Radiopharmaceutical for Nuclear Medicine Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies Radiopharmaceutical for Nuclear Medicine Revenue Market Share (2021-2026)
Table 29. World Radiopharmaceutical for Nuclear Medicine Market Size by Type, (USD Million), 2021 & 2025 & 2032
Table 30. World Radiopharmaceutical for Nuclear Medicine Market Size Value by Type (2021-2026) & (USD Million)
Table 31. World Radiopharmaceutical for Nuclear Medicine Market Size by Type (2027-2032) & (USD Million)
Table 32. World Radiopharmaceutical for Nuclear Medicine Market Size by Disease, (USD Million), 2021 & 2025 & 2032
Table 33. World Radiopharmaceutical for Nuclear Medicine Market Size Value by Disease (2021-2026) & (USD Million)
Table 34. World Radiopharmaceutical for Nuclear Medicine Market Size by Disease (2027-2032) & (USD Million)
Table 35. World Radiopharmaceutical for Nuclear Medicine Market Size by Application, (USD Million), 2021 & 2025 & 2032
Table 36. World Radiopharmaceutical for Nuclear Medicine Market Size by Application (2021-2026) & (USD Million)
Table 37. World Radiopharmaceutical for Nuclear Medicine Market Size by Application (2027-2032) & (USD Million)
Table 38. Cardinal Health Basic Information, Manufacturing Base and Competitors
Table 39. Cardinal Health Major Business
Table 40. Cardinal Health Radiopharmaceutical for Nuclear Medicine Product and Services
Table 41. Cardinal Health Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 42. Cardinal Health Recent Developments/Updates
Table 43. Cardinal Health Competitive Strengths & Weaknesses
Table 44. GE Healthcare Basic Information, Manufacturing Base and Competitors
Table 45. GE Healthcare Major Business
Table 46. GE Healthcare Radiopharmaceutical for Nuclear Medicine Product and Services
Table 47. GE Healthcare Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 48. GE Healthcare Recent Developments/Updates
Table 49. GE Healthcare Competitive Strengths & Weaknesses
Table 50. Lantheus Medical Imaging Basic Information, Manufacturing Base and Competitors
Table 51. Lantheus Medical Imaging Major Business
Table 52. Lantheus Medical Imaging Radiopharmaceutical for Nuclear Medicine Product and Services
Table 53. Lantheus Medical Imaging Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 54. Lantheus Medical Imaging Recent Developments/Updates
Table 55. Lantheus Medical Imaging Competitive Strengths & Weaknesses
Table 56. Bayer Basic Information, Manufacturing Base and Competitors
Table 57. Bayer Major Business
Table 58. Bayer Radiopharmaceutical for Nuclear Medicine Product and Services
Table 59. Bayer Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 60. Bayer Recent Developments/Updates
Table 61. Bayer Competitive Strengths & Weaknesses
Table 62. Eli Lilly Basic Information, Manufacturing Base and Competitors
Table 63. Eli Lilly Major Business
Table 64. Eli Lilly Radiopharmaceutical for Nuclear Medicine Product and Services
Table 65. Eli Lilly Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 66. Eli Lilly Recent Developments/Updates
Table 67. Eli Lilly Competitive Strengths & Weaknesses
Table 68. Bracco Imaging Basic Information, Manufacturing Base and Competitors
Table 69. Bracco Imaging Major Business
Table 70. Bracco Imaging Radiopharmaceutical for Nuclear Medicine Product and Services
Table 71. Bracco Imaging Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 72. Bracco Imaging Recent Developments/Updates
Table 73. Bracco Imaging Competitive Strengths & Weaknesses
Table 74. Curium Pharma Basic Information, Manufacturing Base and Competitors
Table 75. Curium Pharma Major Business
Table 76. Curium Pharma Radiopharmaceutical for Nuclear Medicine Product and Services
Table 77. Curium Pharma Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 78. Curium Pharma Recent Developments/Updates
Table 79. Curium Pharma Competitive Strengths & Weaknesses
Table 80. Jubilant Pharmova Basic Information, Manufacturing Base and Competitors
Table 81. Jubilant Pharmova Major Business
Table 82. Jubilant Pharmova Radiopharmaceutical for Nuclear Medicine Product and Services
Table 83. Jubilant Pharmova Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 84. Jubilant Pharmova Recent Developments/Updates
Table 85. Jubilant Pharmova Competitive Strengths & Weaknesses
Table 86. Aurobindo Pharma Basic Information, Manufacturing Base and Competitors
Table 87. Aurobindo Pharma Major Business
Table 88. Aurobindo Pharma Radiopharmaceutical for Nuclear Medicine Product and Services
Table 89. Aurobindo Pharma Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 90. Aurobindo Pharma Recent Developments/Updates
Table 91. Aurobindo Pharma Competitive Strengths & Weaknesses
Table 92. Novartis Basic Information, Manufacturing Base and Competitors
Table 93. Novartis Major Business
Table 94. Novartis Radiopharmaceutical for Nuclear Medicine Product and Services
Table 95. Novartis Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 96. Novartis Recent Developments/Updates
Table 97. Novartis Competitive Strengths & Weaknesses
Table 98. Siemens Basic Information, Manufacturing Base and Competitors
Table 99. Siemens Major Business
Table 100. Siemens Radiopharmaceutical for Nuclear Medicine Product and Services
Table 101. Siemens Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 102. Siemens Recent Developments/Updates
Table 103. Siemens Competitive Strengths & Weaknesses
Table 104. NTP Radioisotopes Basic Information, Manufacturing Base and Competitors
Table 105. NTP Radioisotopes Major Business
Table 106. NTP Radioisotopes Radiopharmaceutical for Nuclear Medicine Product and Services
Table 107. NTP Radioisotopes Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 108. NTP Radioisotopes Recent Developments/Updates
Table 109. NTP Radioisotopes Competitive Strengths & Weaknesses
Table 110. ANSTO Basic Information, Manufacturing Base and Competitors
Table 111. ANSTO Major Business
Table 112. ANSTO Radiopharmaceutical for Nuclear Medicine Product and Services
Table 113. ANSTO Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 114. ANSTO Recent Developments/Updates
Table 115. ANSTO Competitive Strengths & Weaknesses
Table 116. Polatom Basic Information, Manufacturing Base and Competitors
Table 117. Polatom Major Business
Table 118. Polatom Radiopharmaceutical for Nuclear Medicine Product and Services
Table 119. Polatom Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 120. Polatom Recent Developments/Updates
Table 121. Polatom Competitive Strengths & Weaknesses
Table 122. China Isotope & Radiation Basic Information, Manufacturing Base and Competitors
Table 123. China Isotope & Radiation Major Business
Table 124. China Isotope & Radiation Radiopharmaceutical for Nuclear Medicine Product and Services
Table 125. China Isotope & Radiation Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 126. China Isotope & Radiation Recent Developments/Updates
Table 127. China Isotope & Radiation Competitive Strengths & Weaknesses
Table 128. Yantai Dongcheng Basic Information, Manufacturing Base and Competitors
Table 129. Yantai Dongcheng Major Business
Table 130. Yantai Dongcheng Radiopharmaceutical for Nuclear Medicine Product and Services
Table 131. Yantai Dongcheng Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 132. Yantai Dongcheng Recent Developments/Updates
Table 133. Yantai Dongcheng Competitive Strengths & Weaknesses
Table 134. Seed Biological Pharmacy Basic Information, Manufacturing Base and Competitors
Table 135. Seed Biological Pharmacy Major Business
Table 136. Seed Biological Pharmacy Radiopharmaceutical for Nuclear Medicine Product and Services
Table 137. Seed Biological Pharmacy Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 138. Seed Biological Pharmacy Recent Developments/Updates
Table 139. Seed Biological Pharmacy Competitive Strengths & Weaknesses
Table 140. Global Key Players of Radiopharmaceutical for Nuclear Medicine Upstream (Raw Materials)
Table 141. Global Radiopharmaceutical for Nuclear Medicine Typical Customers
Table 1. World Radiopharmaceutical for Nuclear Medicine Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World Radiopharmaceutical for Nuclear Medicine Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World Radiopharmaceutical for Nuclear Medicine Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World Radiopharmaceutical for Nuclear Medicine Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World Radiopharmaceutical for Nuclear Medicine Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Radiopharmaceutical for Nuclear Medicine Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World Radiopharmaceutical for Nuclear Medicine Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World Radiopharmaceutical for Nuclear Medicine Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World Radiopharmaceutical for Nuclear Medicine Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key Radiopharmaceutical for Nuclear Medicine Players in 2025
Table 12. World Radiopharmaceutical for Nuclear Medicine Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global Radiopharmaceutical for Nuclear Medicine Company Evaluation Quadrant
Table 14. Head Office of Key Radiopharmaceutical for Nuclear Medicine Players
Table 15. Radiopharmaceutical for Nuclear Medicine Market: Company Product Type Footprint
Table 16. Radiopharmaceutical for Nuclear Medicine Market: Company Product Application Footprint
Table 17. Radiopharmaceutical for Nuclear Medicine Mergers & Acquisitions Activity
Table 18. United States VS China Radiopharmaceutical for Nuclear Medicine Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China Radiopharmaceutical for Nuclear Medicine Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 20. United States Based Radiopharmaceutical for Nuclear Medicine Companies, Headquarters (States, Country)
Table 21. United States Based Companies Radiopharmaceutical for Nuclear Medicine Revenue, (2021-2026) & (USD Million)
Table 22. United States Based Companies Radiopharmaceutical for Nuclear Medicine Revenue Market Share (2021-2026)
Table 23. China Based Radiopharmaceutical for Nuclear Medicine Companies, Headquarters (Province, Country)
Table 24. China Based Companies Radiopharmaceutical for Nuclear Medicine Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies Radiopharmaceutical for Nuclear Medicine Revenue Market Share (2021-2026)
Table 26. Rest of World Based Radiopharmaceutical for Nuclear Medicine Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies Radiopharmaceutical for Nuclear Medicine Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies Radiopharmaceutical for Nuclear Medicine Revenue Market Share (2021-2026)
Table 29. World Radiopharmaceutical for Nuclear Medicine Market Size by Type, (USD Million), 2021 & 2025 & 2032
Table 30. World Radiopharmaceutical for Nuclear Medicine Market Size Value by Type (2021-2026) & (USD Million)
Table 31. World Radiopharmaceutical for Nuclear Medicine Market Size by Type (2027-2032) & (USD Million)
Table 32. World Radiopharmaceutical for Nuclear Medicine Market Size by Disease, (USD Million), 2021 & 2025 & 2032
Table 33. World Radiopharmaceutical for Nuclear Medicine Market Size Value by Disease (2021-2026) & (USD Million)
Table 34. World Radiopharmaceutical for Nuclear Medicine Market Size by Disease (2027-2032) & (USD Million)
Table 35. World Radiopharmaceutical for Nuclear Medicine Market Size by Application, (USD Million), 2021 & 2025 & 2032
Table 36. World Radiopharmaceutical for Nuclear Medicine Market Size by Application (2021-2026) & (USD Million)
Table 37. World Radiopharmaceutical for Nuclear Medicine Market Size by Application (2027-2032) & (USD Million)
Table 38. Cardinal Health Basic Information, Manufacturing Base and Competitors
Table 39. Cardinal Health Major Business
Table 40. Cardinal Health Radiopharmaceutical for Nuclear Medicine Product and Services
Table 41. Cardinal Health Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 42. Cardinal Health Recent Developments/Updates
Table 43. Cardinal Health Competitive Strengths & Weaknesses
Table 44. GE Healthcare Basic Information, Manufacturing Base and Competitors
Table 45. GE Healthcare Major Business
Table 46. GE Healthcare Radiopharmaceutical for Nuclear Medicine Product and Services
Table 47. GE Healthcare Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 48. GE Healthcare Recent Developments/Updates
Table 49. GE Healthcare Competitive Strengths & Weaknesses
Table 50. Lantheus Medical Imaging Basic Information, Manufacturing Base and Competitors
Table 51. Lantheus Medical Imaging Major Business
Table 52. Lantheus Medical Imaging Radiopharmaceutical for Nuclear Medicine Product and Services
Table 53. Lantheus Medical Imaging Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 54. Lantheus Medical Imaging Recent Developments/Updates
Table 55. Lantheus Medical Imaging Competitive Strengths & Weaknesses
Table 56. Bayer Basic Information, Manufacturing Base and Competitors
Table 57. Bayer Major Business
Table 58. Bayer Radiopharmaceutical for Nuclear Medicine Product and Services
Table 59. Bayer Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 60. Bayer Recent Developments/Updates
Table 61. Bayer Competitive Strengths & Weaknesses
Table 62. Eli Lilly Basic Information, Manufacturing Base and Competitors
Table 63. Eli Lilly Major Business
Table 64. Eli Lilly Radiopharmaceutical for Nuclear Medicine Product and Services
Table 65. Eli Lilly Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 66. Eli Lilly Recent Developments/Updates
Table 67. Eli Lilly Competitive Strengths & Weaknesses
Table 68. Bracco Imaging Basic Information, Manufacturing Base and Competitors
Table 69. Bracco Imaging Major Business
Table 70. Bracco Imaging Radiopharmaceutical for Nuclear Medicine Product and Services
Table 71. Bracco Imaging Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 72. Bracco Imaging Recent Developments/Updates
Table 73. Bracco Imaging Competitive Strengths & Weaknesses
Table 74. Curium Pharma Basic Information, Manufacturing Base and Competitors
Table 75. Curium Pharma Major Business
Table 76. Curium Pharma Radiopharmaceutical for Nuclear Medicine Product and Services
Table 77. Curium Pharma Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 78. Curium Pharma Recent Developments/Updates
Table 79. Curium Pharma Competitive Strengths & Weaknesses
Table 80. Jubilant Pharmova Basic Information, Manufacturing Base and Competitors
Table 81. Jubilant Pharmova Major Business
Table 82. Jubilant Pharmova Radiopharmaceutical for Nuclear Medicine Product and Services
Table 83. Jubilant Pharmova Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 84. Jubilant Pharmova Recent Developments/Updates
Table 85. Jubilant Pharmova Competitive Strengths & Weaknesses
Table 86. Aurobindo Pharma Basic Information, Manufacturing Base and Competitors
Table 87. Aurobindo Pharma Major Business
Table 88. Aurobindo Pharma Radiopharmaceutical for Nuclear Medicine Product and Services
Table 89. Aurobindo Pharma Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 90. Aurobindo Pharma Recent Developments/Updates
Table 91. Aurobindo Pharma Competitive Strengths & Weaknesses
Table 92. Novartis Basic Information, Manufacturing Base and Competitors
Table 93. Novartis Major Business
Table 94. Novartis Radiopharmaceutical for Nuclear Medicine Product and Services
Table 95. Novartis Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 96. Novartis Recent Developments/Updates
Table 97. Novartis Competitive Strengths & Weaknesses
Table 98. Siemens Basic Information, Manufacturing Base and Competitors
Table 99. Siemens Major Business
Table 100. Siemens Radiopharmaceutical for Nuclear Medicine Product and Services
Table 101. Siemens Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 102. Siemens Recent Developments/Updates
Table 103. Siemens Competitive Strengths & Weaknesses
Table 104. NTP Radioisotopes Basic Information, Manufacturing Base and Competitors
Table 105. NTP Radioisotopes Major Business
Table 106. NTP Radioisotopes Radiopharmaceutical for Nuclear Medicine Product and Services
Table 107. NTP Radioisotopes Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 108. NTP Radioisotopes Recent Developments/Updates
Table 109. NTP Radioisotopes Competitive Strengths & Weaknesses
Table 110. ANSTO Basic Information, Manufacturing Base and Competitors
Table 111. ANSTO Major Business
Table 112. ANSTO Radiopharmaceutical for Nuclear Medicine Product and Services
Table 113. ANSTO Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 114. ANSTO Recent Developments/Updates
Table 115. ANSTO Competitive Strengths & Weaknesses
Table 116. Polatom Basic Information, Manufacturing Base and Competitors
Table 117. Polatom Major Business
Table 118. Polatom Radiopharmaceutical for Nuclear Medicine Product and Services
Table 119. Polatom Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 120. Polatom Recent Developments/Updates
Table 121. Polatom Competitive Strengths & Weaknesses
Table 122. China Isotope & Radiation Basic Information, Manufacturing Base and Competitors
Table 123. China Isotope & Radiation Major Business
Table 124. China Isotope & Radiation Radiopharmaceutical for Nuclear Medicine Product and Services
Table 125. China Isotope & Radiation Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 126. China Isotope & Radiation Recent Developments/Updates
Table 127. China Isotope & Radiation Competitive Strengths & Weaknesses
Table 128. Yantai Dongcheng Basic Information, Manufacturing Base and Competitors
Table 129. Yantai Dongcheng Major Business
Table 130. Yantai Dongcheng Radiopharmaceutical for Nuclear Medicine Product and Services
Table 131. Yantai Dongcheng Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 132. Yantai Dongcheng Recent Developments/Updates
Table 133. Yantai Dongcheng Competitive Strengths & Weaknesses
Table 134. Seed Biological Pharmacy Basic Information, Manufacturing Base and Competitors
Table 135. Seed Biological Pharmacy Major Business
Table 136. Seed Biological Pharmacy Radiopharmaceutical for Nuclear Medicine Product and Services
Table 137. Seed Biological Pharmacy Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 138. Seed Biological Pharmacy Recent Developments/Updates
Table 139. Seed Biological Pharmacy Competitive Strengths & Weaknesses
Table 140. Global Key Players of Radiopharmaceutical for Nuclear Medicine Upstream (Raw Materials)
Table 141. Global Radiopharmaceutical for Nuclear Medicine Typical Customers
LIST OF FIGURES
Figure 1. Radiopharmaceutical for Nuclear Medicine Picture
Figure 2. World Radiopharmaceutical for Nuclear Medicine Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Radiopharmaceutical for Nuclear Medicine Total Revenue (2021-2032) & (USD Million)
Figure 4. World Radiopharmaceutical for Nuclear Medicine Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World Radiopharmaceutical for Nuclear Medicine Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company Radiopharmaceutical for Nuclear Medicine Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company Radiopharmaceutical for Nuclear Medicine Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company Radiopharmaceutical for Nuclear Medicine Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company Radiopharmaceutical for Nuclear Medicine Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company Radiopharmaceutical for Nuclear Medicine Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company Radiopharmaceutical for Nuclear Medicine Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company Radiopharmaceutical for Nuclear Medicine Revenue (2021-2032) & (USD Million)
Figure 13. Radiopharmaceutical for Nuclear Medicine Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Radiopharmaceutical for Nuclear Medicine Consumption Value (2021-2032) & (USD Million)
Figure 16. World Radiopharmaceutical for Nuclear Medicine Consumption Value Market Share by Region (2021-2032)
Figure 17. United States Radiopharmaceutical for Nuclear Medicine Consumption Value (2021-2032) & (USD Million)
Figure 18. China Radiopharmaceutical for Nuclear Medicine Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe Radiopharmaceutical for Nuclear Medicine Consumption Value (2021-2032) & (USD Million)
Figure 20. Japan Radiopharmaceutical for Nuclear Medicine Consumption Value (2021-2032) & (USD Million)
Figure 21. South Korea Radiopharmaceutical for Nuclear Medicine Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN Radiopharmaceutical for Nuclear Medicine Consumption Value (2021-2032) & (USD Million)
Figure 23. India Radiopharmaceutical for Nuclear Medicine Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of Radiopharmaceutical for Nuclear Medicine by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Radiopharmaceutical for Nuclear Medicine Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Radiopharmaceutical for Nuclear Medicine Markets in 2025
Figure 27. United States VS China: Radiopharmaceutical for Nuclear Medicine Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Radiopharmaceutical for Nuclear Medicine Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World Radiopharmaceutical for Nuclear Medicine Market Size by Type, (USD Million), 2021 & 2025 & 2032
Figure 30. World Radiopharmaceutical for Nuclear Medicine Market Size Market Share by Type in 2025
Figure 31. Diagnosis Nuclear Medicine
Figure 32. Therapeutic Nuclear Medicine
Figure 33. World Radiopharmaceutical for Nuclear Medicine Market Size Market Share by Type (2021-2032)
Figure 34. World Radiopharmaceutical for Nuclear Medicine Market Size by Disease, (USD Million), 2021 & 2025 & 2032
Figure 35. World Radiopharmaceutical for Nuclear Medicine Market Size Market Share by Disease in 2025
Figure 36. Technetium-99m
Figure 37. Fluorine-18
Figure 38. Iodine-123
Figure 39. Iodine-131
Figure 40. Lutetium-177
Figure 41. Other
Figure 42. World Radiopharmaceutical for Nuclear Medicine Market Size Market Share by Disease (2021-2032)
Figure 43. Oncology
Figure 44. Cardiology
Figure 45. Other
Figure 46. World Radiopharmaceutical for Nuclear Medicine Market Size by Application, (USD Million), 2021 & 2025 & 2032
Figure 47. World Radiopharmaceutical for Nuclear Medicine Market Size Market Share by Application in 2025
Figure 48. Hospital
Figure 49. Imaging Center
Figure 50. Others
Figure 51. World Radiopharmaceutical for Nuclear Medicine Market Size Market Share by Application (2021-2032)
Figure 52. Radiopharmaceutical for Nuclear Medicine Industrial Chain
Figure 53. Methodology
Figure 54. Research Process and Data Source
Figure 1. Radiopharmaceutical for Nuclear Medicine Picture
Figure 2. World Radiopharmaceutical for Nuclear Medicine Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Radiopharmaceutical for Nuclear Medicine Total Revenue (2021-2032) & (USD Million)
Figure 4. World Radiopharmaceutical for Nuclear Medicine Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World Radiopharmaceutical for Nuclear Medicine Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company Radiopharmaceutical for Nuclear Medicine Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company Radiopharmaceutical for Nuclear Medicine Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company Radiopharmaceutical for Nuclear Medicine Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company Radiopharmaceutical for Nuclear Medicine Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company Radiopharmaceutical for Nuclear Medicine Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company Radiopharmaceutical for Nuclear Medicine Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company Radiopharmaceutical for Nuclear Medicine Revenue (2021-2032) & (USD Million)
Figure 13. Radiopharmaceutical for Nuclear Medicine Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Radiopharmaceutical for Nuclear Medicine Consumption Value (2021-2032) & (USD Million)
Figure 16. World Radiopharmaceutical for Nuclear Medicine Consumption Value Market Share by Region (2021-2032)
Figure 17. United States Radiopharmaceutical for Nuclear Medicine Consumption Value (2021-2032) & (USD Million)
Figure 18. China Radiopharmaceutical for Nuclear Medicine Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe Radiopharmaceutical for Nuclear Medicine Consumption Value (2021-2032) & (USD Million)
Figure 20. Japan Radiopharmaceutical for Nuclear Medicine Consumption Value (2021-2032) & (USD Million)
Figure 21. South Korea Radiopharmaceutical for Nuclear Medicine Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN Radiopharmaceutical for Nuclear Medicine Consumption Value (2021-2032) & (USD Million)
Figure 23. India Radiopharmaceutical for Nuclear Medicine Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of Radiopharmaceutical for Nuclear Medicine by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Radiopharmaceutical for Nuclear Medicine Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Radiopharmaceutical for Nuclear Medicine Markets in 2025
Figure 27. United States VS China: Radiopharmaceutical for Nuclear Medicine Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Radiopharmaceutical for Nuclear Medicine Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World Radiopharmaceutical for Nuclear Medicine Market Size by Type, (USD Million), 2021 & 2025 & 2032
Figure 30. World Radiopharmaceutical for Nuclear Medicine Market Size Market Share by Type in 2025
Figure 31. Diagnosis Nuclear Medicine
Figure 32. Therapeutic Nuclear Medicine
Figure 33. World Radiopharmaceutical for Nuclear Medicine Market Size Market Share by Type (2021-2032)
Figure 34. World Radiopharmaceutical for Nuclear Medicine Market Size by Disease, (USD Million), 2021 & 2025 & 2032
Figure 35. World Radiopharmaceutical for Nuclear Medicine Market Size Market Share by Disease in 2025
Figure 36. Technetium-99m
Figure 37. Fluorine-18
Figure 38. Iodine-123
Figure 39. Iodine-131
Figure 40. Lutetium-177
Figure 41. Other
Figure 42. World Radiopharmaceutical for Nuclear Medicine Market Size Market Share by Disease (2021-2032)
Figure 43. Oncology
Figure 44. Cardiology
Figure 45. Other
Figure 46. World Radiopharmaceutical for Nuclear Medicine Market Size by Application, (USD Million), 2021 & 2025 & 2032
Figure 47. World Radiopharmaceutical for Nuclear Medicine Market Size Market Share by Application in 2025
Figure 48. Hospital
Figure 49. Imaging Center
Figure 50. Others
Figure 51. World Radiopharmaceutical for Nuclear Medicine Market Size Market Share by Application (2021-2032)
Figure 52. Radiopharmaceutical for Nuclear Medicine Industrial Chain
Figure 53. Methodology
Figure 54. Research Process and Data Source
